The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor-A is widely regarded as the principal stimulator of angiogenesis required for tumour growth. VEGF is generated as multiple isoforms of two families, the pro-angiogenic family generated by proximal splice site selection in the terminal exon, termed VEGFxxx, and the anti-angiogenic family formed by distal splice site selection in the terminal exon, termed VEGFxxxb, where xxx is the amino acid number. The most studied isoforms, VEGF165 and VEGF165b have been shown to be present in tumour and normal tissues respectively. VEGF165b has been shown to inhibit VEGF- and hypoxia-induced angiogenesis, and VEGF-induced cell migration and proliferation in vitro. Here we show that overexpression of VEGF165b by tumour cells inhibits the growth of prostate carcinoma, Ewing's sarcoma and renal cell carcinoma in xenografted mouse tumour models. Moreover, VEGF165b overexpression inhibited tumour cell-mediated migration and proliferation of endothelial cells. These data show that overexpression of VEGF165b can inhibit growth of multiple tumour types in vivo indicating that VEGF165b has potential as an anti-angiogenic, anti-tumour strategy in a number of different tumour types, either by control of VEGF165b expression by regulation of splicing, overexpression of VEGF165b, or therapeutic delivery of VEGF165b to tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“VEGF has been generally considered in over 20 000 papers since 1990 as a pro-angiogenic tumour-enhancing endothelial-specific growth factor (Ferrara, 2002) and successful antiangiogenic agents have been directed at VEGF in cancer and eye disease (Gragoudas et al, 2004; Hurwitz et al, 2004).”
BackgroundVEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant
Woolard, J., Wang, W.-Y., Bevan, H. S., Qiu, Y., Morbidelli, L., Pritchard-Jones, R. O., Cui, T.-G., Sugiono, M., Waine, E., Perrin, R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0934 · Cited by 451
Self-citation
Cited by
Hallmarks of alternative splicing in cancer
Oltean, S., & Bates, D. O. (2014) · Oncogene · doi:10.1038/onc.2013.533 · Cited by 664
Self-citationRNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Harper, S. J., & Bates, D. O. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2505 · Cited by 514
Self-citationMolecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
Peach, C. J., Mignone, V. W., Arruda, M. A., Alcobia, D. C., Hill, S. J., Kilpatrick, L. E., & Woolard, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041264 · Cited by 512
Self-citationVascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Niu, G., & Chen, X. (2010) · Current Drug Targets · doi:10.2174/138945010791591395 · Cited by 451
Metadata
- Authors
- Rennel, E. S., Waine, E., Guan, H., Schüler, Y., Leenders, W., Woolard, J., Sugiono, M., Gillatt, D., Kleinerman, E. S., Bates, D. O., & Harper, S. J.
- Venue
- British Journal of Cancer
- Published
- 2008-03-18
- Volume
- 98
- Issue
- 7
- Pages
- 1250-1257
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2065863629
- Cited by
- 124
- References
- 3
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. https://app.cochat.ai/papers/10.1038/sj.bjc.6604309
- The paper
- Rennel, E. S., Waine, E., Guan, H., Schüler, Y., Leenders, W., Woolard, J., Sugiono, M., Gillatt, D., Kleinerman, E. S., Bates, D. O., & Harper, S. J. (2008). The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604309
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.